These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 19844224)

  • 1. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.
    Huang SM; Temple R; Xiao S; Zhang L; Lesko LJ
    Clin Pharmacol Ther; 2009 Nov; 86(5):475-9. PubMed ID: 19844224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.
    Zhang L; Xu N; Xiao S; Arya V; Zhao P; Lesko LJ; Huang SM
    J Clin Pharmacol; 2012 Jan; 52(1 Suppl):79S-90S. PubMed ID: 22232757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic protein-drug interactions and implications for drug development.
    Huang SM; Zhao H; Lee JI; Reynolds K; Zhang L; Temple R; Lesko LJ
    Clin Pharmacol Ther; 2010 Apr; 87(4):497-503. PubMed ID: 20200513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
    Huang SM; Strong JM; Zhang L; Reynolds KS; Nallani S; Temple R; Abraham S; Habet SA; Baweja RK; Burckart GJ; Chung S; Colangelo P; Frucht D; Green MD; Hepp P; Karnaukhova E; Ko HS; Lee JI; Marroum PJ; Norden JM; Qiu W; Rahman A; Sobel S; Stifano T; Thummel K; Wei XX; Yasuda S; Zheng JH; Zhao H; Lesko LJ
    J Clin Pharmacol; 2008 Jun; 48(6):662-70. PubMed ID: 18378963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment.
    Lalonde RL; Wagner JA
    Clin Pharmacol Ther; 2009 Nov; 86(5):557-61. PubMed ID: 19776736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
    Zolnik BS; Sadrieh N
    Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memo to the FDA and ICH: appeal for in vivo drug target identification and target pharmacokinetics Recommendations for improved procedures and requirements.
    Stumpf WE
    Drug Discov Today; 2007 Aug; 12(15-16):594-8. PubMed ID: 17706540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications.
    Zhang Y; Zhang L; Abraham S; Apparaju S; Wu TC; Strong JM; Xiao S; Atkinson AJ; Thummel KE; Leeder JS; Lee C; Burckart GJ; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2009 Mar; 85(3):305-11. PubMed ID: 19020495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
    Huang SM; Temple R; Throckmorton DC; Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
    Zineh I; Pacanowski MA
    Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling and predicting drug pharmacokinetics in patients with renal impairment.
    Rowland Yeo K; Aarabi M; Jamei M; Rostami-Hodjegan A
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):261-74. PubMed ID: 22115405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How a US regulator can encourage new science.
    Throckmorton DC
    Clin Pharmacol Ther; 2009 Nov; 86(5):471-2. PubMed ID: 19844222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
    Little S
    IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH
    Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics and drugs.
    FDA Consum; 2004; 38(1):7. PubMed ID: 15032193
    [No Abstract]   [Full Text] [Related]  

  • 17. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
    Bottomley A; Jones D; Claassens L
    Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Conference on Harmonisation; guidance on E2E Pharmacovigilance Planning; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Apr; 70(62):16827-8. PubMed ID: 15803631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Conference on Harmonisation; guidance on Q8(R1) Pharmaceutical Development; addition of annex; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jun; 74(109):27325-6. PubMed ID: 19588572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulated drug bioanalysis for human pharmacokinetic studies and therapeutic drug management.
    Huang Y; Shi R; Gee W; Bonderud R
    Bioanalysis; 2012 Aug; 4(15):1919-31. PubMed ID: 22943622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.